MOLN (MOLN) Stock Price & Analysis
MOLN (MOLN) fell 2.02% to USD 3.89 as of July 26, 2026 at 08:56 UTC, according to Nexqual real-time market data.
MOLN last closed at USD 3.97; the session ranged USD 3.89–3.89 on volume of 1,041 shares. Market capitalization is $145.92M, with a 52-week range of USD 3.41–5.36 (NMS). Source: Nexqual, July 26, 2026 at 08:56 UTC.
Key Statistics (as of July 26, 2026 at 08:56 UTC)
| Price | USD 3.89 |
|---|---|
| Change | ▼ 2.02% (down) |
| Previous Close | USD 3.97 |
| Open | USD 3.89 |
| Day Range | USD 3.89 – 3.89 |
| 52-Week Range | USD 3.41 – 5.36 |
| Volume | 1,041 shares |
| Market Cap | $145.92M |
| Exchange | NMS |
Technical Analysis (MOLN)
Nexqual's technical model rates MOLN "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 26, 2026 at 08:56 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 44.95 (neutral) |
| vs SMA50 | Below (USD 3.94) |
| MACD | 0 (positive) |
Analyst Ratings (MOLN)
Wall Street analysts rate MOLN "Strong Buy" based on 5 analysts, with a mean price target of USD 11 (range USD 3.71–16.77), per Nexqual as of July 26, 2026 at 08:56 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 11 |
| High Target | USD 16.77 |
| Low Target | USD 3.71 |
| Buy / Hold / Sell | 4 / 1 / 0 |
Earnings (MOLN)
| EPS Estimate | USD -0.35 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.36 vs est -0.3 ▼ miss |
| 2025-09-30 | USD -0.33 vs est -0.37 ▲ beat |
| 2025-06-30 | USD -0.56 vs est -0.44 ▼ miss |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financials & Fundamentals (MOLN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -59.01% |
| Debt / Equity | 4.89 |
| Current Ratio | 9.43 |
| Total Cash | $78.77M |
| Total Debt | $3.34M |
| Free Cash Flow | $-25.20M |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financial Health Score (MOLN)
Nexqual rates MOLN's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 08:56 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $79M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$48M |
| Efficiency | Critical — ROE -59%, ROA -28.8% |
Ownership (MOLN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +9.58% |
| Shares Outstanding | 37.51M |
| Float | 19.92M |
| Short % of Float | +0.01% |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Leadership (MOLN)
MOLN is led by Patrick Amstutz (age 50), Co-Founder, CEO, Member of Management Board & Director, per Nexqual as of July 26, 2026 at 08:56 UTC.
| Co-Founder, CEO, Member of Management Board & Director | Patrick Amstutz (age 50) |
|---|---|
| COO & Member of Management Board | Alexander Zurcher (age 50) |
| Chief Scientific Officer & Member of the Management Board | Martin Steegmaier (age 59) |
| Senior Vice President of Targeted Radio Therapeutics | Daniel Steiner |
Major Backers & Investors (MOLN)
Notable institutional backers of MOLN include Suvretta Capital Management, LLC, BVF Inc., according to Nexqual as of July 26, 2026 at 08:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Suvretta Capital Management, LLC | 5.5% |
| BVF Inc. | 3.35% |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | USD 2.11 | ▼ 1.86% |
| RLYB | Rallybio Corporation | USD 16.31 | ▼ 1.87% |
| PHVS | Pharvaris N.V. | USD 34.17 | ▼ 0.55% |
| DSGN | Design Therapeutics, Inc. | USD 11.78 | ▲ 0% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:56 UTC. This page is informational and not investment advice.